Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL. Passet M, Kim R, Gachet S, Sigaux F, et al. Blood 2022;139:3505-3518.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Passet M, Kim R, Gachet S, Sigaux F, et al. Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL. Blood 2022;139:3505-3518.
PMID: 35316324